Mei Mei Hu
Oprichter bij VAXXINITY, INC.
Vermogen: 9 M $ op 30-04-2024
Actieve functies van Mei Mei Hu
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
VAXXINITY, INC. | Directeur/Bestuurslid | 01-01-2014 | - |
Algemeen Directeur | 01-01-2014 | - | |
Oprichter | 01-01-2014 | - | |
President | 01-01-2014 | - | |
UNITED BIOPHARMA INC | Directeur/Bestuurslid | 01-03-2020 | - |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Algemeen Directeur | 01-03-2020 | - |
Loopbaan van Mei Mei Hu
Eerdere bekende functies van Mei Mei Hu
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Shen Lian Biotechnology Co. Ltd. | Directeur/Bestuurslid | 01-01-2010 | 01-01-2014 |
United Neuroscience LLC | Directeur/Bestuurslid | 01-10-2014 | - |
Opleiding van Mei Mei Hu
University of Pennsylvania | Undergraduate Degree |
Harvard Law School | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Taiwan | 2 |
China | 2 |
Operationeel
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Founder | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
VAXXINITY, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
United BioPharma, Inc.
United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
Shen Lian Biotechnology Co. Ltd. | |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Health Technology |
United Neuroscience LLC |
- Beurs
- Insiders
- Mei Mei Hu
- Ervaring